$LFCR
LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr

$lfcr Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000100528623000057 Filed on March 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4
Revenue	$27.60M	$38.80M
YoY Change	-48.0%	-70.04%
Cost Of Revenue	$21.62M	$31.69M
YoY Change	-44.81%	-72.79%
Gross Profit	$5.978M	$7.108M
YoY Change	-56.98%	-45.29%
Gross Profit Margin	21.66%	18.32%
Selling, General & Admin	$10.97M	$10.77M
YoY Change	12.82%	-22.13%
% of Gross Profit	183.54%	151.56%
Research & Development	$1.964M	$2.118M
YoY Change	-4.47%	-22.08%
% of Gross Profit	32.85%	29.8%
Depreciation & Amortization	$3.150M	$2.880M
YoY Change	-10.74%	-51.23%
% of Gross Profit	52.69%	40.52%
Operating Expenses	$15.68M	$15.01M
YoY Change	-11.16%	-69.99%
Operating Profit	-$9.699M	-$7.906M
YoY Change	158.57%	-78.65%
Interest Expense	$5.818M	$4.219M
YoY Change	41.73%	-2.63%
% of Operating Profit
Other Income/Expense, Net	$34.00K	-$336.0K
YoY Change	-92.51%	-525.32%
Pretax Income	-$15.39M	-$12.45M
YoY Change	108.49%	-69.84%
Income Tax	$70.00K	$4.000K
% Of Pretax Income
Net Earnings	-$40.19M	-$12.45M
YoY Change	212.78%	-67.62%
Net Earnings / Revenue	-145.62%	-32.08%
Basic Earnings Per Share	-$1.33	-$0.42
Diluted Earnings Per Share	-$1.33	-$0.42
COMMON SHARES
Basic Shares Outstanding	30.32M shares	29.60M shares
Diluted Shares Outstanding	30.30M shares	29.63M shares

Balance Sheet

Concept	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.000M	$6.800M
YoY Change	61.81%	523.28%
Cash & Equivalents	$2.950M	$6.830M
Short-Term Investments
Other Short-Term Assets	$4.400M	$7.000M
YoY Change	-36.45%	-19.73%
Inventory	$48.70M	$77.52M
Prepaid Expenses
Receivables	$32.37M	$35.69M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$88.44M	$127.1M
YoY Change	-33.02%	-17.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$120.8M	$118.9M
YoY Change	-1.96%	-33.95%
Goodwill	$13.88M	$13.88M
YoY Change	-59.07%	-62.81%
Intangibles	$4.400M	$7.400M
YoY Change	-74.27%	-70.78%
Long-Term Investments
YoY Change
Other Assets	$2.710M	$2.605M
YoY Change	-11.09%	-19.57%
Total Long-Term Assets	$147.7M	$152.0M
YoY Change	-23.68%	-43.21%
TOTAL ASSETS
Total Short-Term Assets	$88.44M	$127.1M
Total Long-Term Assets	$147.7M	$152.0M
Total Assets	$236.2M	$279.1M
YoY Change	-27.47%	-33.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.76M	$27.97M
YoY Change	-26.24%	-52.67%
Accrued Expenses	$20.20M	$20.00M
YoY Change	-29.21%	-0.03%
Deferred Revenue	$2.711M	$731.0K
YoY Change	67.97%	-36.98%
Short-Term Debt	$0.00	$48.00M
YoY Change	-100.0%	14.29%
Long-Term Debt Due	$0.00	$98.95M
YoY Change
Total Short-Term Liabilities	$37.67M	$195.7M
YoY Change	-58.17%	60.06%
LONG-TERM LIABILITIES
Long-Term Debt	$98.96M	$0.00
YoY Change	24.33%	-100.0%
Other Long-Term Liabilities	$203.0K	$201.0K
YoY Change	-62.68%	-94.84%
Total Long-Term Liabilities	$99.17M	$201.0K
YoY Change	23.74%	-99.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.67M	$195.7M
Total Long-Term Liabilities	$99.17M	$201.0K
Total Liabilities	$163.4M	$204.9M
YoY Change	-9.96%	-22.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$140.1M	-$99.90M
YoY Change	531.38%	969.81%
Common Stock	$30.00K	$30.00K
YoY Change	3.45%	3.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.21M	$74.17M
YoY Change
Total Liabilities & Shareholders Equity	$236.2M	$279.1M
YoY Change	-27.47%	-33.89%

Cashflow Statement

Concept	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$40.19M	-$12.45M
YoY Change	212.78%	-67.62%
Depreciation, Depletion And Amortization	$3.150M	$2.880M
YoY Change	-10.74%	-51.23%
Cash From Operating Activities	-$12.69M	-$2.950M
YoY Change	-36.96%	-42.57%
INVESTING ACTIVITIES
Capital Expenditures	$6.140M	$3.250M
YoY Change	-211.05%	-163.76%
Acquisitions
YoY Change
Other Investing Activities	$12.53M	$0.00
YoY Change	-82.96%
Cash From Investing Activities	$6.400M	-$3.260M
YoY Change	-90.59%	-36.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.410M	8.810M
YoY Change	-105.12%	-10.81%
NET CHANGE
Cash From Operating Activities	-12.69M	-2.950M
Cash From Investing Activities	6.400M	-3.260M
Cash From Financing Activities	2.410M	8.810M
Net Change In Cash	-3.880M	2.600M
YoY Change	-608.52%	-830.34%
FREE CASH FLOW
Cash From Operating Activities	-$12.69M	-$2.950M
Capital Expenditures	$6.140M	$3.250M
Free Cash Flow	-$18.83M	-$6.200M
YoY Change	28.97%	15400.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001005286
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-29
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q4	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q4	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q4	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q4	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	LANDEC CORPORATION
	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	LFCR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30319208	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6830000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1643000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35689000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48172000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	77524000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	66845000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7049000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7052000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	127092000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	123712000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118852000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118531000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7951000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8580000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	13881000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	13881000	usd
CY2022Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	7400000	usd
CY2022Q2	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	8700000	usd
CY2022Q4	lndc	Finite Lived Customer Lists Net FiniteLivedCustomerListsNet	1292000	usd
CY2022Q2	lndc	Finite Lived Customer Lists Net FiniteLivedCustomerListsNet	1400000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2605000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3002000	usd
CY2022Q4	us-gaap	Assets Assets	279073000	usd
CY2022Q2	us-gaap	Assets Assets	277806000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27971000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	15802000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4602000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9238000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10426000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7647000	usd
CY2022Q4	lndc	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	5013000	usd
CY2022Q2	lndc	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	5026000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	731000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	919000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	48000000	usd
CY2022Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	40000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	98953000	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	98178000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	195696000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	176810000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	lndc	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	8999000	usd
CY2022Q2	lndc	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	9983000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	126000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	201000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	204906000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30297000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30297000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29513000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29513000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	30000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	30000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174036000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167352000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99899000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76099000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-586000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	74167000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	90697000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	279073000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	277806000	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	38802000	usd
CY2021Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	43452000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	82157000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	85084000	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31694000	usd
CY2021Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28737000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	68797000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	59934000	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	7108000	usd
CY2021Q4	us-gaap	Gross Profit GrossProfit	14715000	usd
	us-gaap	Gross Profit GrossProfit	13360000	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2118000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3729000	usd
CY2021Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8012000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21435000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17482000	usd
CY2022Q4	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1300000	usd
CY2021Q4	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1300000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Restructuring Charges RestructuringCharges	823000	usd
CY2021Q4	us-gaap	Restructuring Charges RestructuringCharges	707000	usd
	us-gaap	Restructuring Charges RestructuringCharges	1870000	usd
	us-gaap	Restructuring Charges RestructuringCharges	2541000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	15014000	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	10575000	usd
	us-gaap	Operating Expenses OperatingExpenses	28771000	usd
	us-gaap	Operating Expenses OperatingExpenses	23752000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7906000	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	4140000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15411000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	1398000	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	16000	usd
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	31000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	46000	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	4219000	usd
CY2021Q4	us-gaap	Interest Expense InterestExpense	3094000	usd
	us-gaap	Interest Expense InterestExpense	7897000	usd
	us-gaap	Interest Expense InterestExpense	9772000	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-336000	usd
CY2021Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	79000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-515000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	188000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12445000	usd
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1144000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23792000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8140000	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2021Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3085000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4736000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-12449000	usd
CY2021Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	4229000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-23800000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3404000	usd
CY2022Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	0	usd
CY2021Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-42409000	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	0	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-44714000	usd
CY2022Q4	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	usd
CY2021Q4	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	261000	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-200000	usd
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	usd
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-42670000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-44514000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-12449000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.42
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.14
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.80
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.12
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.45
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.51
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.63
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.42
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.14
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.80
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.12
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.45
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.51
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.63
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29634000	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29471000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29605000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29448000	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29634000	shares
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29471000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29605000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29448000	shares
CY2022Q4	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	0	usd
CY2021Q4	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-100000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-16000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-190000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	286000	usd
CY2021Q4	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	176000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	586000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	542000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	286000	usd
CY2021Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	176000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	542000	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12163000	usd
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38265000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23214000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47376000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	90697000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	67000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	785000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11351000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	300000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	80364000	usd
CY2022Q4	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	142000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1108000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-12449000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	286000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	74167000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	202784000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	428000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	620000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-9477000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	366000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	193865000	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2021Q4	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	84000	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	686000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-38441000	usd
CY2021Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	176000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	156202000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47918000	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	1300000	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	32057000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7237000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10959000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2108000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1893000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1306000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-13000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-4963000	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	-92000	usd
	lndc	Discontinued Operations Credit Loss Expense Reversal DiscontinuedOperationsCreditLossExpenseReversal	0	usd
	lndc	Discontinued Operations Credit Loss Expense Reversal DiscontinuedOperationsCreditLossExpenseReversal	196000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-86000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	111000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-12483000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4541000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10679000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9770000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	585000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1784000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11730000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15148000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4636000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5090000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2777000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1163000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-188000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	30000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4481000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4306000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	3135000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6182000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13010000	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	45100000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1082000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3047000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33172000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	76000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	41426000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	8800000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	26000000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	800000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	13000000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	209000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	512000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	132000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12715000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-29070000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5187000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-204000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1643000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1295000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6830000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1091000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2700000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1105000	usd
CY2022Q4	lndc	Number Of Product Category NumberOfProductCategory	2	product
CY2022Q4	lndc	Number Of Revenue Category NumberOfRevenueCategory	2	revenue
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	38882000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	33029000	usd
	us-gaap	Fiscal Period FiscalPeriod	<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fiscal year is the 52- or 53-week period that ends on the last Sunday of May with quarters within each year ending on the last Sunday of August, November, and February; however, in instances where the last Sunday would result in a quarter being 12-weeks in length, the Company’s policy is to extend that quarter to the following Sunday. A 14th week is included in the fiscal year every five or six years to realign the Company’s fiscal quarters with calendar quarters.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three and six months ended November 27, 2022 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in Curation Foods’ business and the order patterns of Lifecore’s customers which may lead to significant fluctuations in Lifecore Biomedical’s quarterly results of operations.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies; sales returns and credit losses; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets and goodwill), and inventory; and the valuation and recognition of stock-based compensation.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results may differ from management’s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 27, 2022, the Company had cash and cash equivalents of $6.8 million and outstanding borrowings of $147.0 million, net of issuance costs. The Company continues to experience unfavorable market conditions leading to lower than projected sales proceeds from the disposition of its Curation Foods businesses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment, which occurred on the date of the filing of this Form 10-Q, to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern within one year following the date the accompanying consolidated financial statements are being issued (the “Filing Date”).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to meet its liquidity needs for one year following the Filing Date will largely depend on its ability to generate cash in the future. As of November 27, 2022, the Company incurred net losses of $23.8 million, and the Company’s ability to generate cash in the future is subject to general economic, financial, competitive, legislative, regulatory, and other factors that are beyond the Company’s control. Based on the Company’s financial projections as of the Filing Date, the Company does not believe that it will have adequate liquidity to meet its obligations for at least one year following the Filing Date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company further considered how these factors and uncertainties have and could impact its ability to meet the obligations specified in the New Credit Agreements with the Lenders (as defined in Note 6 - Debt) for at least one year following the Filing Date. As of the Filing Date, the Company determined that it was not in compliance with the covenant under the New </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit Agreements requiring the timely filing of financial statements. In addition, the inclusion of a going concern explanatory paragraph in the auditor’s report issued by Ernst and Young LLP in connection with the restated audited financial statements for the year ended May 29, 2022 included in the Company’s Annual Report on Form 10-K/A for the year ended May 29, 2022 filed on the date of this report also violates the covenants under the New Credit Agreements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, based on the Company’s current financial projections for the one-year period following the Filing Date, the Company anticipates that it will not be in compliance with certain financial covenants under the New Credit Agreements during the one-year period following the Filing Date, including the minimum fixed charge coverage ratio covenant for the fiscal quarters ending May 30, 2023 through November 30, 2023; the maximum leverage ratio covenant as of the fiscal quarters ending May 30, 2023 through November 30, 2023; the minimum liquidity covenant for each of the fiscal quarters ended as of February 26, 2023 through May 30, 2024; and the minimum Lifecore gross profit covenant for the fiscal quarters ending February 26, 2023 through August 30, 2023. Pursuant to the terms of the New Credit Agreements, as a result of the Company’s failure to comply with the covenants described above, the agents and the lenders under the New Credit Agreements are entitled to immediately cancel all unfunded commitments and to accelerate the maturity of all of the outstanding debt thereunder, at which time all such outstanding borrowings would become immediately due and payable by the Company. In addition, as a result of such defaults, under the New Credit Agreements, the Company will be subject to increased interest rates for any outstanding borrowings thereunder prior to repayment and, even if the agent and the lenders under the Revolving Credit Facility (as defined in Note 6 – Debt) do not exercise their rights to immediately accelerate all outstanding obligations, such lenders may refuse to fund additional borrowings thereunder, which the Company relies upon for short-term liquidity needs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company is currently in default, as of the Filing Date, the agents and the Lenders have not taken any action to accelerate the maturity of the debt under the New Credit Agreements, nor have the Lenders under the Revolving Credit Facility indicated that they intend to prevent the Company from incurring additional borrowings thereunder. In such an event, however, the Company does not currently have sufficient liquidity to fund payment of the amounts that would be due under the New Credit Agreements nor does management have projected future cash flows to repay these outstanding borrowings under the New Credit Agreements if such amounts were to become payable. The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the New Credit Agreements or providing additional liquidity needed for its operations, could have a material adverse effect on its business, results of operations, liquidity and financial condition. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In response to these conditions, the Company is currently in negotiations with the Lenders to seek a forbearance and amendment agreement to remedy the Company’s current and anticipated noncompliance with its covenants under the New Credit Agreements. The Company also intends to conduct a review of its strategic alternatives, which may involve seeking additional or alternative financing or the sale of all or a portion of the Company. These processes are ongoing, however, and there can be no assurances that they will result in the completion of any such amendment, transaction or other alternative that would alleviate such conditions under the New Credit Agreements or the circumstances that give rise to substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the Filing Date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Company determined that it cannot be certain that the Company’s plans and initiatives would be effectively implemented within one year after the Filing Date. Without giving effect to the Company’s plans and initiatives, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties within one year after the Filing Date. The existence of these conditions and events raise substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the Filing Date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for one year following the Filing Date. As such, the accompanying unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, all outstanding borrowings under the New Credit Agreements are classified as short term on the Consolidated Balance Sheets as of November 27, 2022 and May 29, 2022 contained in these unaudited consolidated financial statements.</span></div>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6830000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1643000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1091000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1159000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	136000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6830000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1643000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1091000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1295000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	26959000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	24221000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	11683000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	9595000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	77524000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	66845000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	65000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	65000	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	85000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-14000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	71000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	4700000	usd
CY2022Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	5500000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	98178000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	400000	usd
CY2021Q2	us-gaap	Insurance Recoveries InsuranceRecoveries	1600000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	98953000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	17850	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	743050	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3400000	shares
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1108000	usd
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	686000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1893000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1306000	usd
CY2010Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000	usd
CY2022Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	3800000	usd
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-12449000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-38441000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47918000	usd
CY2022Q4	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29634000	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29471000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29605000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29448000	shares
CY2022Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29634000	shares
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29471000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29605000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29448000	shares
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.63
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000.0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4700000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.094
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1000000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1000000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	900000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	103712000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	103712000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	103712000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	103712000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	4759000	usd
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	5534000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	98953000	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	98178000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2020Q4	lndc	Number Of Credit Agreements NumberOfCreditAgreements	2	creditagreement
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2022Q4	lndc	Number Of Natural Food Brands NumberOfNaturalFoodBrands	3	brand
CY2022Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	38802000	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	7108000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-12449000	usd
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	2442000	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	16000	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	4219000	usd
CY2022Q4	lndc	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	82157000	usd
	us-gaap	Gross Profit GrossProfit	13360000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-23800000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	6391000	usd
	us-gaap	Investment Income Dividend InvestmentIncomeDividend	0	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	31000	usd
	us-gaap	Interest Expense InterestExpense	7897000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
	lndc	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
CY2021Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	43452000	usd
CY2021Q4	us-gaap	Gross Profit GrossProfit	14715000	usd
CY2021Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4229000	usd
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-42670000	usd
CY2021Q4	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	2585000	usd
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000	usd
CY2021Q4	us-gaap	Interest Expense InterestExpense	3094000	usd
CY2021Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3085000	usd
CY2021Q4	lndc	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	85084000	usd
	us-gaap	Gross Profit GrossProfit	25150000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3404000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-44514000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	5039000	usd
	us-gaap	Investment Income Dividend InvestmentIncomeDividend	0	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	46000	usd
	us-gaap	Interest Expense InterestExpense	9772000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4736000	usd
	lndc	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
CY2022Q4	us-gaap	Restructuring Costs RestructuringCosts	823000	usd
	us-gaap	Restructuring Costs RestructuringCosts	1870000	usd
	us-gaap	Restructuring Costs RestructuringCosts	18648000	usd
CY2022Q4	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	23000000	usd

Files In Submission

Name	View Source	Status
lndc-20221127_def.xml	Edgar Link	unprocessable
lndc-20221127_cal.xml	Edgar Link	unprocessable
0001005286-23-000057-index-headers.html	Edgar Link	pending
0001005286-23-000057-index.html	Edgar Link	pending
0001005286-23-000057.txt	Edgar Link	pending
0001005286-23-000057-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lndc-20221127.htm	Edgar Link	pending
lndc-20221127.xsd	Edgar Link	pending
lndc-20221127xexx311.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
lndc-20221127xexx312.htm	Edgar Link	pending
lndc-20221127xexx321.htm	Edgar Link	pending
lndc-20221127xexx322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
lndc-20221127_lab.xml	Edgar Link	unprocessable
lndc-20221127_pre.xml	Edgar Link	unprocessable
lndc-20221127_htm.xml	Edgar Link	completed
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LFCR
LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr

2023 Q1 Form 10-Q Financial Statement

#000100528623000057 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFCR LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr

2023 Q1 Form 10-Q Financial Statement

#000100528623000057 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFCR
LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr